Cadrenal Therapeutics, Inc. Common StockCVKDNASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating

Buy

1 analyst·Low coverage

100%

Rating Distribution

Strong Buy

00%

Buy

1100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 382% higher.

Bear Case

$32.00

+382%

Consensus

$32.00

+382%

Bull Case

$32.00

+382%

Price Range1 analyst

Low

Consensus

High

$32.00

Current Target

Current Price

$6.64

Upside to Target

$25.36

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-5.42(2 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev—

EPS—

FY2028

Rev+166.67%

EPS—

FY2029

Rev—

EPS—

Earnings Surprises

Beat rate:33%(3/9 quarters)

Avg surprise:-2.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Nov 11, 2024H.C. Wainwright

Cadrenal Therapeutics (CVKD) PT Raised to $32 at H.C. Wainwright

Target:$32.00

+114.3%from $14.93

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance